Ken Griffin Tg Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $2.43 Million - $3.57 Million	141,100 Added 76.02%	326,700 $7.64 Million
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $467,532 - $673,569	-35,100 Reduced 15.9%	185,600 $3.3 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $1.83 Million - $3 Million	-140,800 Reduced 38.95%	220,700 $3.36 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $470,272 - $1.32 Million	70,400 Added 24.18%	361,500 $6.17 Million
Q3 2023 Nov 14, 2023	SELL	$8.36 - $26.5 $3.22 Million - $10.2 Million	-385,000 Reduced 56.94%	291,100 $2.43 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $3.48 Million - $7.88 Million	225,100 Added 49.91%	676,100 $16.8 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $19.34 $5.07 Million - $9.58 Million	-495,500 Reduced 52.35%	451,000 $6.78 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $277,053 - $654,199	55,300 Added 6.21%	946,500 $11.2 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $659,451 - $1.21 Million	144,300 Added 19.32%	891,200 $5.28 Million

338

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.67B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.